Report Scope
This latest report researches the industry structure, revenue and gross margin. Major players’ headquarters, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Recombinant DNA Technology companies, distributors, end users, industry associations, governments' industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Recombinant DNA Technology market. Further, it explains the major drivers and regional dynamics of the global Recombinant DNA Technology market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable revenue, market share and rank data of the companies for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
Monsanto Company
Roche
Biogen
Amgen
Novartis
Eli Lilly and Company
GenScript
Pfizer Inc.
Novo Nordisk
Sanofi
Merck KGaA
Profacgen
Biocon
GlaxoSmithKline
Cibus
Horizon Discovery Group
New England Biolabs
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides revenue forecast data by type and by application segments based on value for the period 2017-2028.
Recombinant DNA Technology Segment by Type
Therapeutic Agent
Vaccine
Biotech Crops
Specialty Chemicals
Recombinant DNA Technology Segment by Application
Biotechnology and Pharmaceutical Companies
Academic & Government Research Institutes
Others
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Recombinant DNA Technology market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for Recombinant DNA Technology market size. Analyses of the global market trends, with historic market revenue data for 2017 - 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Recombinant DNA Technology, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Recombinant DNA Technology, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Recombinant DNA Technology revenue, market share and industry ranking of main companies, data from 2017 to 2022. Identification of the major stakeholders in the global Recombinant DNA Technology market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2017 to 2028. Evaluation and forecast the market size for Recombinant DNA Technology revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Monsanto Company, Roche, Biogen, Amgen, Novartis, Eli Lilly and Company, GenScript, Pfizer Inc. and Novo Nordisk, etc.
This latest report researches the industry structure, revenue and gross margin. Major players’ headquarters, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Recombinant DNA Technology companies, distributors, end users, industry associations, governments' industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Recombinant DNA Technology market. Further, it explains the major drivers and regional dynamics of the global Recombinant DNA Technology market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable revenue, market share and rank data of the companies for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
Monsanto Company
Roche
Biogen
Amgen
Novartis
Eli Lilly and Company
GenScript
Pfizer Inc.
Novo Nordisk
Sanofi
Merck KGaA
Profacgen
Biocon
GlaxoSmithKline
Cibus
Horizon Discovery Group
New England Biolabs
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides revenue forecast data by type and by application segments based on value for the period 2017-2028.
Recombinant DNA Technology Segment by Type
Therapeutic Agent
Vaccine
Biotech Crops
Specialty Chemicals
Recombinant DNA Technology Segment by Application
Biotechnology and Pharmaceutical Companies
Academic & Government Research Institutes
Others
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Recombinant DNA Technology market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for Recombinant DNA Technology market size. Analyses of the global market trends, with historic market revenue data for 2017 - 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Recombinant DNA Technology, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Recombinant DNA Technology, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Recombinant DNA Technology revenue, market share and industry ranking of main companies, data from 2017 to 2022. Identification of the major stakeholders in the global Recombinant DNA Technology market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2017 to 2028. Evaluation and forecast the market size for Recombinant DNA Technology revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Monsanto Company, Roche, Biogen, Amgen, Novartis, Eli Lilly and Company, GenScript, Pfizer Inc. and Novo Nordisk, etc.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Recombinant DNA Technology Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Therapeutic Agent
1.2.3 Vaccine
1.2.4 Biotech Crops
1.2.5 Specialty Chemicals
1.3 Market by Application
1.3.1 Global Recombinant DNA Technology Market Growth Rate by Application: 2017 VS 2021 VS 2028
1.3.2 Biotechnology and Pharmaceutical Companies
1.3.3 Academic & Government Research Institutes
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Market Perspective
2.1 Global Recombinant DNA Technology Market Size (2017-2028)
2.2 Recombinant DNA Technology Market Size across Key Geographies Worldwide: 2017 VS 2021 VS 2028
2.3 Global Recombinant DNA Technology Market Size by Region (2017-2022)
2.4 Global Recombinant DNA Technology Market Size Forecast by Region (2023-2028)
2.5 Global Top Recombinant DNA Technology Countries Ranking by Market Size
3 Recombinant DNA Technology Competitive by Company
3.1 Global Recombinant DNA Technology Revenue by Players
3.1.1 Global Recombinant DNA Technology Revenue by Players (2017-2022)
3.1.2 Global Recombinant DNA Technology Market Share by Players (2017-2022)
3.2 Global Recombinant DNA Technology Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Company Covered: Ranking by Recombinant DNA Technology Revenue
3.4 Global Recombinant DNA Technology Market Concentration Ratio
3.4.1 Global Recombinant DNA Technology Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Recombinant DNA Technology Revenue in 2021
3.5 Global Recombinant DNA Technology Key Players Head office and Area Served
3.6 Key Players Recombinant DNA Technology Product Solution and Service
3.7 Date of Enter into Recombinant DNA Technology Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Global Recombinant DNA Technology Breakdown Data by Type
4.1 Global Recombinant DNA Technology Historic Revenue by Type (2017-2022)
4.2 Global Recombinant DNA Technology Forecasted Revenue by Type (2023-2028)
5 Global Recombinant DNA Technology Breakdown Data by Application
5.1 Global Recombinant DNA Technology Historic Market Size by Application (2017-2022)
5.2 Global Recombinant DNA Technology Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Recombinant DNA Technology Revenue by Company (2020-2022)
6.2 North America Recombinant DNA Technology Revenue by Type (2017-2028)
6.3 North America Recombinant DNA Technology Revenue by Application (2017-2028)
6.4 North America Recombinant DNA Technology Revenue by Country (2017-2028)
6.4.1 U.S.
6.4.2 Canada
7 Europe
7.1 Europe Recombinant DNA Technology Revenue by Company (2020-2022)
7.2 Europe Recombinant DNA Technology Revenue by Type (2017-2028)
7.3 Europe Recombinant DNA Technology Revenue by Application (2017-2028)
7.4 Europe Recombinant DNA Technology Revenue by Country (2017-2028)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
8 Asia Pacific
8.1 Asia Pacific Recombinant DNA Technology Revenue by Company (2020-2022)
8.2 Asia Pacific Recombinant DNA Technology Revenue by Type (2017-2028)
8.3 Asia Pacific Recombinant DNA Technology Revenue by Application (2017-2028)
8.4 Asia Pacific Recombinant DNA Technology Revenue by Region (2017-2028)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 India
8.4.5 Australia
8.4.6 China Taiwan
8.4.7 Indonesia
8.4.8 Thailand
8.4.9 Malaysia
9 Latin America
9.1 Latin America Recombinant DNA Technology Revenue by Company (2020-2022)
9.2 Latin America Recombinant DNA Technology Revenue by Type (2017-2028)
9.3 Latin America Recombinant DNA Technology Revenue by Application (2017-2028)
9.4 Latin America Recombinant DNA Technology Revenue by Country (2017-2028)
9.4.1 Mexico
9.4.2 Brazil
9.4.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Recombinant DNA Technology Revenue by Company (2020-2022)
10.2 Middle East and Africa Recombinant DNA Technology Revenue by Type (2017-2028)
10.3 Middle East and Africa Recombinant DNA Technology Revenue by Application (2017-2028)
10.4 Middle East and Africa Recombinant DNA Technology Revenue by Country (2017-2028)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 UAE
11 Company Profiles
11.1 Monsanto Company
11.1.1 Monsanto Company Company Details
11.1.2 Monsanto Company Business Overview
11.1.3 Monsanto Company Recombinant DNA Technology Products and Services
11.1.4 Monsanto Company Recombinant DNA Technology Revenue in Recombinant DNA Technology Business (2017-2022)
11.1.5 Monsanto Company Recombinant DNA Technology SWOT Analysis
11.1.6 Monsanto Company Recent Developments
11.2 Roche
11.2.1 Roche Company Details
11.2.2 Roche Business Overview
11.2.3 Roche Recombinant DNA Technology Products and Services
11.2.4 Roche Recombinant DNA Technology Revenue in Recombinant DNA Technology Business (2017-2022)
11.2.5 Roche Recombinant DNA Technology SWOT Analysis
11.2.6 Roche Recent Developments
11.3 Biogen
11.3.1 Biogen Company Details
11.3.2 Biogen Business Overview
11.3.3 Biogen Recombinant DNA Technology Products and Services
11.3.4 Biogen Recombinant DNA Technology Revenue in Recombinant DNA Technology Business (2017-2022)
11.3.5 Biogen Recombinant DNA Technology SWOT Analysis
11.3.6 Biogen Recent Developments
11.4 Amgen
11.4.1 Amgen Company Details
11.4.2 Amgen Business Overview
11.4.3 Amgen Recombinant DNA Technology Products and Services
11.4.4 Amgen Recombinant DNA Technology Revenue in Recombinant DNA Technology Business (2017-2022)
11.4.5 Amgen Recombinant DNA Technology SWOT Analysis
11.4.6 Amgen Recent Developments
11.5 Novartis
11.5.1 Novartis Company Details
11.5.2 Novartis Business Overview
11.5.3 Novartis Recombinant DNA Technology Products and Services
11.5.4 Novartis Recombinant DNA Technology Revenue in Recombinant DNA Technology Business (2017-2022)
11.5.5 Novartis Recombinant DNA Technology SWOT Analysis
11.5.6 Novartis Recent Developments
11.6 Eli Lilly and Company
11.6.1 Eli Lilly and Company Company Details
11.6.2 Eli Lilly and Company Business Overview
11.6.3 Eli Lilly and Company Recombinant DNA Technology Products and Services
11.6.4 Eli Lilly and Company Recombinant DNA Technology Revenue in Recombinant DNA Technology Business (2017-2022)
11.6.5 Eli Lilly and Company Recombinant DNA Technology SWOT Analysis
11.6.6 Eli Lilly and Company Recent Developments
11.7 GenScript
11.7.1 GenScript Company Details
11.7.2 GenScript Business Overview
11.7.3 GenScript Recombinant DNA Technology Products and Services
11.7.4 GenScript Recombinant DNA Technology Revenue in Recombinant DNA Technology Business (2017-2022)
11.7.5 GenScript Recombinant DNA Technology SWOT Analysis
11.7.6 GenScript Recent Developments
11.8 Pfizer Inc.
11.8.1 Pfizer Inc. Company Details
11.8.2 Pfizer Inc. Business Overview
11.8.3 Pfizer Inc. Recombinant DNA Technology Products and Services
11.8.4 Pfizer Inc. Recombinant DNA Technology Revenue in Recombinant DNA Technology Business (2017-2022)
11.8.5 Pfizer Inc. Recombinant DNA Technology SWOT Analysis
11.8.6 Pfizer Inc. Recent Developments
11.9 Novo Nordisk
11.9.1 Novo Nordisk Company Details
11.9.2 Novo Nordisk Business Overview
11.9.3 Novo Nordisk Recombinant DNA Technology Products and Services
11.9.4 Novo Nordisk Recombinant DNA Technology Revenue in Recombinant DNA Technology Business (2017-2022)
11.9.5 Novo Nordisk Recombinant DNA Technology SWOT Analysis
11.9.6 Novo Nordisk Recent Developments
11.10 Sanofi
11.10.1 Sanofi Company Details
11.10.2 Sanofi Business Overview
11.10.3 Sanofi Recombinant DNA Technology Products and Services
11.10.4 Sanofi Recombinant DNA Technology Revenue in Recombinant DNA Technology Business (2017-2022)
11.10.5 Sanofi Recombinant DNA Technology SWOT Analysis
11.10.6 Sanofi Recent Developments
11.11 Merck KGaA
11.11.1 Merck KGaA Company Details
11.11.2 Merck KGaA Business Overview
11.11.3 Merck KGaA Recombinant DNA Technology Products and Services
11.11.4 Merck KGaA Recombinant DNA Technology Revenue in Recombinant DNA Technology Business (2017-2022)
11.11.5 Merck KGaA Recent Developments
11.12 Profacgen
11.12.1 Profacgen Company Details
11.12.2 Profacgen Business Overview
11.12.3 Profacgen Recombinant DNA Technology Products and Services
11.12.4 Profacgen Recombinant DNA Technology Revenue in Recombinant DNA Technology Business (2017-2022)
11.12.5 Profacgen Recent Developments
11.13 Biocon
11.13.1 Biocon Company Details
11.13.2 Biocon Business Overview
11.13.3 Biocon Recombinant DNA Technology Products and Services
11.13.4 Biocon Recombinant DNA Technology Revenue in Recombinant DNA Technology Business (2017-2022)
11.13.5 Biocon Recent Developments
11.14 GlaxoSmithKline
11.14.1 GlaxoSmithKline Company Details
11.14.2 GlaxoSmithKline Business Overview
11.14.3 GlaxoSmithKline Recombinant DNA Technology Products and Services
11.14.4 GlaxoSmithKline Recombinant DNA Technology Revenue in Recombinant DNA Technology Business (2017-2022)
11.14.5 GlaxoSmithKline Recent Developments
11.15 Cibus
11.15.1 Cibus Company Details
11.15.2 Cibus Business Overview
11.15.3 Cibus Recombinant DNA Technology Products and Services
11.15.4 Cibus Recombinant DNA Technology Revenue in Recombinant DNA Technology Business (2017-2022)
11.15.5 Cibus Recent Developments
11.16 Horizon Discovery Group
11.16.1 Horizon Discovery Group Company Details
11.16.2 Horizon Discovery Group Business Overview
11.16.3 Horizon Discovery Group Recombinant DNA Technology Products and Services
11.16.4 Horizon Discovery Group Recombinant DNA Technology Revenue in Recombinant DNA Technology Business (2017-2022)
11.16.5 Horizon Discovery Group Recent Developments
11.17 New England Biolabs
11.17.1 New England Biolabs Company Details
11.17.2 New England Biolabs Business Overview
11.17.3 New England Biolabs Recombinant DNA Technology Products and Services
11.17.4 New England Biolabs Recombinant DNA Technology Revenue in Recombinant DNA Technology Business (2017-2022)
11.17.5 New England Biolabs Recent Developments
12 Recombinant DNA Technology Market Dynamics
12.1 Recombinant DNA Technology Market Trends
12.2 Recombinant DNA Technology Market Drivers
12.3 Recombinant DNA Technology Market Challenges
12.4 Recombinant DNA Technology Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Recombinant DNA Technology Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Therapeutic Agent
1.2.3 Vaccine
1.2.4 Biotech Crops
1.2.5 Specialty Chemicals
1.3 Market by Application
1.3.1 Global Recombinant DNA Technology Market Growth Rate by Application: 2017 VS 2021 VS 2028
1.3.2 Biotechnology and Pharmaceutical Companies
1.3.3 Academic & Government Research Institutes
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Market Perspective
2.1 Global Recombinant DNA Technology Market Size (2017-2028)
2.2 Recombinant DNA Technology Market Size across Key Geographies Worldwide: 2017 VS 2021 VS 2028
2.3 Global Recombinant DNA Technology Market Size by Region (2017-2022)
2.4 Global Recombinant DNA Technology Market Size Forecast by Region (2023-2028)
2.5 Global Top Recombinant DNA Technology Countries Ranking by Market Size
3 Recombinant DNA Technology Competitive by Company
3.1 Global Recombinant DNA Technology Revenue by Players
3.1.1 Global Recombinant DNA Technology Revenue by Players (2017-2022)
3.1.2 Global Recombinant DNA Technology Market Share by Players (2017-2022)
3.2 Global Recombinant DNA Technology Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Company Covered: Ranking by Recombinant DNA Technology Revenue
3.4 Global Recombinant DNA Technology Market Concentration Ratio
3.4.1 Global Recombinant DNA Technology Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Recombinant DNA Technology Revenue in 2021
3.5 Global Recombinant DNA Technology Key Players Head office and Area Served
3.6 Key Players Recombinant DNA Technology Product Solution and Service
3.7 Date of Enter into Recombinant DNA Technology Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Global Recombinant DNA Technology Breakdown Data by Type
4.1 Global Recombinant DNA Technology Historic Revenue by Type (2017-2022)
4.2 Global Recombinant DNA Technology Forecasted Revenue by Type (2023-2028)
5 Global Recombinant DNA Technology Breakdown Data by Application
5.1 Global Recombinant DNA Technology Historic Market Size by Application (2017-2022)
5.2 Global Recombinant DNA Technology Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Recombinant DNA Technology Revenue by Company (2020-2022)
6.2 North America Recombinant DNA Technology Revenue by Type (2017-2028)
6.3 North America Recombinant DNA Technology Revenue by Application (2017-2028)
6.4 North America Recombinant DNA Technology Revenue by Country (2017-2028)
6.4.1 U.S.
6.4.2 Canada
7 Europe
7.1 Europe Recombinant DNA Technology Revenue by Company (2020-2022)
7.2 Europe Recombinant DNA Technology Revenue by Type (2017-2028)
7.3 Europe Recombinant DNA Technology Revenue by Application (2017-2028)
7.4 Europe Recombinant DNA Technology Revenue by Country (2017-2028)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
8 Asia Pacific
8.1 Asia Pacific Recombinant DNA Technology Revenue by Company (2020-2022)
8.2 Asia Pacific Recombinant DNA Technology Revenue by Type (2017-2028)
8.3 Asia Pacific Recombinant DNA Technology Revenue by Application (2017-2028)
8.4 Asia Pacific Recombinant DNA Technology Revenue by Region (2017-2028)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 India
8.4.5 Australia
8.4.6 China Taiwan
8.4.7 Indonesia
8.4.8 Thailand
8.4.9 Malaysia
9 Latin America
9.1 Latin America Recombinant DNA Technology Revenue by Company (2020-2022)
9.2 Latin America Recombinant DNA Technology Revenue by Type (2017-2028)
9.3 Latin America Recombinant DNA Technology Revenue by Application (2017-2028)
9.4 Latin America Recombinant DNA Technology Revenue by Country (2017-2028)
9.4.1 Mexico
9.4.2 Brazil
9.4.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Recombinant DNA Technology Revenue by Company (2020-2022)
10.2 Middle East and Africa Recombinant DNA Technology Revenue by Type (2017-2028)
10.3 Middle East and Africa Recombinant DNA Technology Revenue by Application (2017-2028)
10.4 Middle East and Africa Recombinant DNA Technology Revenue by Country (2017-2028)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 UAE
11 Company Profiles
11.1 Monsanto Company
11.1.1 Monsanto Company Company Details
11.1.2 Monsanto Company Business Overview
11.1.3 Monsanto Company Recombinant DNA Technology Products and Services
11.1.4 Monsanto Company Recombinant DNA Technology Revenue in Recombinant DNA Technology Business (2017-2022)
11.1.5 Monsanto Company Recombinant DNA Technology SWOT Analysis
11.1.6 Monsanto Company Recent Developments
11.2 Roche
11.2.1 Roche Company Details
11.2.2 Roche Business Overview
11.2.3 Roche Recombinant DNA Technology Products and Services
11.2.4 Roche Recombinant DNA Technology Revenue in Recombinant DNA Technology Business (2017-2022)
11.2.5 Roche Recombinant DNA Technology SWOT Analysis
11.2.6 Roche Recent Developments
11.3 Biogen
11.3.1 Biogen Company Details
11.3.2 Biogen Business Overview
11.3.3 Biogen Recombinant DNA Technology Products and Services
11.3.4 Biogen Recombinant DNA Technology Revenue in Recombinant DNA Technology Business (2017-2022)
11.3.5 Biogen Recombinant DNA Technology SWOT Analysis
11.3.6 Biogen Recent Developments
11.4 Amgen
11.4.1 Amgen Company Details
11.4.2 Amgen Business Overview
11.4.3 Amgen Recombinant DNA Technology Products and Services
11.4.4 Amgen Recombinant DNA Technology Revenue in Recombinant DNA Technology Business (2017-2022)
11.4.5 Amgen Recombinant DNA Technology SWOT Analysis
11.4.6 Amgen Recent Developments
11.5 Novartis
11.5.1 Novartis Company Details
11.5.2 Novartis Business Overview
11.5.3 Novartis Recombinant DNA Technology Products and Services
11.5.4 Novartis Recombinant DNA Technology Revenue in Recombinant DNA Technology Business (2017-2022)
11.5.5 Novartis Recombinant DNA Technology SWOT Analysis
11.5.6 Novartis Recent Developments
11.6 Eli Lilly and Company
11.6.1 Eli Lilly and Company Company Details
11.6.2 Eli Lilly and Company Business Overview
11.6.3 Eli Lilly and Company Recombinant DNA Technology Products and Services
11.6.4 Eli Lilly and Company Recombinant DNA Technology Revenue in Recombinant DNA Technology Business (2017-2022)
11.6.5 Eli Lilly and Company Recombinant DNA Technology SWOT Analysis
11.6.6 Eli Lilly and Company Recent Developments
11.7 GenScript
11.7.1 GenScript Company Details
11.7.2 GenScript Business Overview
11.7.3 GenScript Recombinant DNA Technology Products and Services
11.7.4 GenScript Recombinant DNA Technology Revenue in Recombinant DNA Technology Business (2017-2022)
11.7.5 GenScript Recombinant DNA Technology SWOT Analysis
11.7.6 GenScript Recent Developments
11.8 Pfizer Inc.
11.8.1 Pfizer Inc. Company Details
11.8.2 Pfizer Inc. Business Overview
11.8.3 Pfizer Inc. Recombinant DNA Technology Products and Services
11.8.4 Pfizer Inc. Recombinant DNA Technology Revenue in Recombinant DNA Technology Business (2017-2022)
11.8.5 Pfizer Inc. Recombinant DNA Technology SWOT Analysis
11.8.6 Pfizer Inc. Recent Developments
11.9 Novo Nordisk
11.9.1 Novo Nordisk Company Details
11.9.2 Novo Nordisk Business Overview
11.9.3 Novo Nordisk Recombinant DNA Technology Products and Services
11.9.4 Novo Nordisk Recombinant DNA Technology Revenue in Recombinant DNA Technology Business (2017-2022)
11.9.5 Novo Nordisk Recombinant DNA Technology SWOT Analysis
11.9.6 Novo Nordisk Recent Developments
11.10 Sanofi
11.10.1 Sanofi Company Details
11.10.2 Sanofi Business Overview
11.10.3 Sanofi Recombinant DNA Technology Products and Services
11.10.4 Sanofi Recombinant DNA Technology Revenue in Recombinant DNA Technology Business (2017-2022)
11.10.5 Sanofi Recombinant DNA Technology SWOT Analysis
11.10.6 Sanofi Recent Developments
11.11 Merck KGaA
11.11.1 Merck KGaA Company Details
11.11.2 Merck KGaA Business Overview
11.11.3 Merck KGaA Recombinant DNA Technology Products and Services
11.11.4 Merck KGaA Recombinant DNA Technology Revenue in Recombinant DNA Technology Business (2017-2022)
11.11.5 Merck KGaA Recent Developments
11.12 Profacgen
11.12.1 Profacgen Company Details
11.12.2 Profacgen Business Overview
11.12.3 Profacgen Recombinant DNA Technology Products and Services
11.12.4 Profacgen Recombinant DNA Technology Revenue in Recombinant DNA Technology Business (2017-2022)
11.12.5 Profacgen Recent Developments
11.13 Biocon
11.13.1 Biocon Company Details
11.13.2 Biocon Business Overview
11.13.3 Biocon Recombinant DNA Technology Products and Services
11.13.4 Biocon Recombinant DNA Technology Revenue in Recombinant DNA Technology Business (2017-2022)
11.13.5 Biocon Recent Developments
11.14 GlaxoSmithKline
11.14.1 GlaxoSmithKline Company Details
11.14.2 GlaxoSmithKline Business Overview
11.14.3 GlaxoSmithKline Recombinant DNA Technology Products and Services
11.14.4 GlaxoSmithKline Recombinant DNA Technology Revenue in Recombinant DNA Technology Business (2017-2022)
11.14.5 GlaxoSmithKline Recent Developments
11.15 Cibus
11.15.1 Cibus Company Details
11.15.2 Cibus Business Overview
11.15.3 Cibus Recombinant DNA Technology Products and Services
11.15.4 Cibus Recombinant DNA Technology Revenue in Recombinant DNA Technology Business (2017-2022)
11.15.5 Cibus Recent Developments
11.16 Horizon Discovery Group
11.16.1 Horizon Discovery Group Company Details
11.16.2 Horizon Discovery Group Business Overview
11.16.3 Horizon Discovery Group Recombinant DNA Technology Products and Services
11.16.4 Horizon Discovery Group Recombinant DNA Technology Revenue in Recombinant DNA Technology Business (2017-2022)
11.16.5 Horizon Discovery Group Recent Developments
11.17 New England Biolabs
11.17.1 New England Biolabs Company Details
11.17.2 New England Biolabs Business Overview
11.17.3 New England Biolabs Recombinant DNA Technology Products and Services
11.17.4 New England Biolabs Recombinant DNA Technology Revenue in Recombinant DNA Technology Business (2017-2022)
11.17.5 New England Biolabs Recent Developments
12 Recombinant DNA Technology Market Dynamics
12.1 Recombinant DNA Technology Market Trends
12.2 Recombinant DNA Technology Market Drivers
12.3 Recombinant DNA Technology Market Challenges
12.4 Recombinant DNA Technology Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
Research Methodology
SECONDARY RESEARCH
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.
PRIMARY RESEARCH
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.
MARKET ENGINEERING
The market engineering phase involves analysing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.
EXPERT VALIDATION
The market engineered data is verified and validated by a number of experts, both in-house and external.
REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.